Scheduled and unscheduled combination chemotherapy in the treatment of squamous cell lung cancer (cyclophosphamide, adriamycin, vincristine and bleomycin, with and without cis-platinum).

@article{Jones1983ScheduledAU,
  title={Scheduled and unscheduled combination chemotherapy in the treatment of squamous cell lung cancer (cyclophosphamide, adriamycin, vincristine and bleomycin, with and without cis-platinum).},
  author={Derek H Jones and N. M. Bleehen and Ron M Grant and Piers Nicholas Plowman and J. Trevor Roberts and Karol Sikora and James Watson and Carolyn Wiltshire},
  journal={Anticancer research},
  year={1983},
  volume={3 4},
  pages={235-8}
}
Fifty four patients with squamous cell lung cancer, treated with Cyclophosphamide (750 mg/m2), Adriamycin (50 mg/m2), Vincristine (1.5 mg/m2) and Bleomycin (30 mg) (CAVB) in a 2 day scheduled regime, showed an overall median survival time (MST) of 32 weeks (28 weeks for non-responders and 46.5 weeks for responders--a non-significant difference). The… CONTINUE READING